Dequalinium induces cell death in human leukemia cells by early mitochondrial alterations which enhance ROS

Pilar Sancho1, Eva Galeano, Elena Nieto

  • 1Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Campus Universitario, Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain.

Leukemia Research
|January 26, 2007
PubMed

Insights

Dequalinium (DQA) shows selective cancer cell toxicity by disrupting mitochondria. NB4 cells undergo apoptosis via intrinsic pathways, while K562 cells exhibit greater resistance to DQA treatment.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Dequalinium (DQA) is investigated as a potential antitumoral agent.
  • DQA exhibits preferential accumulation in cancer cell mitochondria.

Purpose of the Study:

  • To elucidate the mechanisms underlying Dequalinium (DQA) cytotoxicity.
  • To understand the differential response of cancer cell lines to DQA.

Main Methods:

  • Treatment of NB4 and K562 cancer cell lines with DQA.
  • Monitoring of mitochondrial membrane potential, cytochrome c release, superoxide anion production, and ATP levels.
  • Assessment of apoptosis induction via caspase-9/caspase-3 dependent pathways.

Main Results:

  • DQA rapidly induced mitochondrial membrane depolarization in NB4 and K562 cells within 30 minutes at high concentrations.
  • NB4 cells exhibited apoptosis, characterized by cytochrome c release, superoxide overproduction, and ATP depletion, mediated by the intrinsic caspase pathway.
  • K562 cells demonstrated higher resistance to DQA compared to NB4 cells, with prolonged viability.

Conclusions:

  • DQA induces cytotoxicity through mitochondrial dysfunction and intrinsic apoptosis pathway activation.
  • Cancer cell line sensitivity to DQA varies, with NB4 cells being more susceptible than K562 cells.
  • DQA's selective mitochondrial targeting offers potential for targeted cancer therapy development.